52
Participants
Start Date
September 15, 2021
Primary Completion Date
July 7, 2025
Study Completion Date
September 30, 2025
Zanidatamab
Administered intravenously (IV)
Evorpacept
Administered IV
Magee-Womens Hospital of UPMC, Pittsburgh
Florida Cancer Specialists, Sarasota
University Hospitals Cleveland Medical Center, Cleveland
University of Wisconsin - Madison, Madison
The University of Texas MD Anderson Cancer Center, Houston
UCLA Department of Medicine Hematology/Oncology, Los Angeles
UC San Diego - Moores Cancer Center, La Jolla
UC Irvine Health - Chao Family Comprehensive Cancer Center, Orange
Northwest Medical Specialties, PLLC, Tacoma
Astera Cancer Care, East Brunswick
University of Vermont Medical Center, Burlington
Lead Sponsor
Collaborators (1)
ALX Oncology Inc.
INDUSTRY
Jazz Pharmaceuticals
INDUSTRY